Acute pancreatitis epidemiology and demographics

Acute pancreatitis Microchapters
Home
American College of Gastroenterology Guidelines
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acute Pancreatitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
History and Symptoms
Physical Examination
Laboratory Findings
Abdominal X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Approach to Therapy
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute pancreatitis epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute pancreatitis epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acute pancreatitis epidemiology and demographics
CDC on Acute pancreatitis epidemiology and demographics
Acute pancreatitis epidemiology and demographics in the news
Blogs on Acute pancreatitis epidemiology and demographics
Directions to Hospitals Treating Acute pancreatitis
Risk calculators and risk factors for Acute pancreatitis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]

Epidemiology and Demographics

Overview

This microchapter covers the incidence, prevalence, mortality, temporal trends, and demographic distribution (age, sex, race/ethnicity) of acute pancreatitis (AP) at global and national levels. Risk factors for developing AP are covered in a dedicated microchapter; etiology-specific epidemiology is referenced here only insofar as it explains demographic patterns.

Incidence

Global incidence of AP is estimated at 13–49 per 100,000 person-years depending on region and methodology, with higher rates in high-income countries. In 2021, the Global Burden of Disease (GBD) study estimated 2.75 million incident cases of AP worldwide, with the highest burden in Eastern Europe (age-standardized pancreatitis incidence ~99 per 100,000, including acute and chronic forms). A landmark 2022 systematic review and meta-analysis (Iannuzzi et al., 44 studies) found the global incidence is increasing at 3.07% per year (95% CI 2.30%–3.84%), with increases observed in North America (AAPC 3.67%) and Europe (AAPC 2.77%).

In the United States, AP is among the most common GI causes of hospitalization, producing >288,000 admissions annually at a cost exceeding $2.6 billion. Hospitalization for AP increased approximately 30% over the past decade. A 2026 US population-based analysis (TriNetX, 120 million individuals) reported age-standardized incidence rising from 23 per 100,000 in 1999 to 117 per 100,000 in 2024 (AAPC 4.81%), though this higher figure likely reflects inclusion of outpatient encounters and coding changes in addition to true incidence increases. When restricted to inpatient admissions only, US incidence estimates are approximately 40–60 per 100,000.

The increase in AP incidence is likely multifactorial, potentially driven by rising rates of obesity, metabolic syndrome, and associated gallstone disease, as well as improved diagnostic recognition and coding. A 2026 US study found that alcohol-induced AP was the only etiology with a statistically significant increase in incidence since 2016, particularly among females.

Global trends from GBD 2021 show a nuanced picture: the overall global age-standardized incidence rate has slightly declined (APC −0.25%), but incidence is increasing in low and low-middle SDI countries. This divergence highlights growing disparities in AP burden by socioeconomic development.

Mortality

Overall AP mortality (case fatality) is approximately 1%–2%, consistent with the pooled estimate of 1.97% (95% CI 1.55%–2.39%) from the Iannuzzi 2022 meta-analysis. Case fatality has decreased over time due to improvements in critical care and minimally invasive management, but the overall population mortality rate has remained relatively unchanged because of increasing incidence, with approximately 9,000 deaths in 2021 when all pancreatitis (acute and chronic) listed anywhere on the death certificate is considered, though only ~3,300 deaths in 2020 listed acute pancreatitis specifically as the underlying cause. In 2021, GBD estimated 122,420 AP deaths globally.

US pancreatitis mortality rates declined 18% from 2006–2019 but rose sharply (25%) from 2019–2021 during the COVID-19 pandemic. Mortality is highest among American Indian/Alaska Native persons and lowest among Asian/Pacific Islander individuals.

Deaths from alcohol-associated AP increased 120% from 2011–2020 while non-alcohol AP deaths remained stable. Among racial/ethnic groups, alcohol-associated AP mortality was highest in non-Hispanic Black individuals (0.21/100,000), whereas non-alcohol AP mortality was highest among AI/AN persons (1.13/100,000).

Severity-stratified mortality (persistent organ failure 25%–46%; infected necrosis with organ failure ~35%) is detailed in the Natural History, Complications, and Prognosis microchapter.

Age

AP incidence increases with age. Peak burden occurs in middle-aged and older adults, with GBD data showing the highest rates among those ≥65 years. However, an upward incidence trend has been noted in younger adults aged 15–25.

Pediatric AP is now recognized as more common than previously appreciated. Incidence in children is estimated at 3.6–13.2 per 100,000 depending on methodology (inpatient-only vs. including outpatient encounters). A large US private insurance database estimated pediatric AP incidence at 12.3 per 100,000 when outpatient encounters were included. The global pediatric AP incidence is increasing at 5.44% per year (95% CI 0.52%–10.36%), faster than in adults. However, recent US data suggest the incidence may have stabilized since 2007–2014. Biliary/obstructive factors, medications, and systemic diseases are the most common causes of childhood AP, differing from the adult pattern. In the United Kingdom, childhood AP incidence was reported at 0.78 per 100,000/year, with a sevenfold higher rate among Pakistani children (4.55/100,000). Globally, GBD 2021 estimated a pediatric (ages 0–19) pancreatitis age-standardized incidence of 7.18 per 100,000, with declining mortality over time.

Sex

The risk of AP is similar between men and women overall. GBD 2021 data show a male-to-female incidence ratio of approximately 1.27:1 and a mortality ratio of 1.94:1. The higher mortality in men is largely attributable to higher rates of alcohol-related AP.

When stratified by etiology, important sex differences emerge:

• Gallstone AP is more common in women (reflecting higher gallstone prevalence)
• Alcohol-related AP is more common in men
• Hypertriglyceridemic AP, hypercalcemic AP, and malignancy-related AP are more common in men

The dose-response relationship between alcohol and AP also differs by sex: it follows a J-shaped (nonlinear) pattern in women but a monotonic increase in men.

Race and Ethnicity

AP disproportionately affects certain racial and ethnic minority groups:

• African Americans are approximately 2-fold more likely to develop AP compared with White Americans. They are also less likely to be transferred to tertiary care centers and more likely to live in underserved neighborhoods, implicating social determinants of health.
• Hispanic patients experience greater rates of organ failure (acute kidney injury and shock) and longer emergency department wait times.
• American Indian/Alaska Native persons have the highest pancreatitis mortality among all racial/ethnic groups in the US and experienced a sharp mortality increase during 2019–2021.
• New Zealand Māori have among the highest reported AP incidence rates worldwide, with a higher rate of gallstone pancreatitis compared with non-Māori.
• Asian individuals generally have the lowest AP prevalence and mortality.

Pancreatitis prevalence in the US is highest among Black and American Indian/Alaska Native individuals across multiple insurance databases.

Healthcare Burden

AP generates substantial healthcare costs. In the US:

• >288,000 hospital admissions annually
• $2.6 billion in annual healthcare costs
• Gallstone AP has higher hospitalization charges than alcohol-related AP ($61,182 vs. $37,982) due to increased use of imaging, ERCP, and longer length of stay
• Disease severity is the key determinant of healthcare costs
• Pancreatitis claims-based prevalence was 0.19% among privately insured, 0.48% among Medicare, and 0.44% among Medicaid beneficiaries (2021)

Clinically Actionable Recommendations

1. Recognize that AP incidence is increasing, particularly alcohol-related AP in recent years, and maintain a broad differential for etiology.
2. Be aware of racial/ethnic disparities: African American and American Indian/Alaska Native patients face disproportionate AP burden and may benefit from targeted risk factor modification and equitable access to tertiary care.
3. Consider AP in children presenting with abdominal pain — pediatric AP is no longer rare (incidence overlaps with the lower end of adult ranges).
4. Recognize that AP mortality, while declining over decades, increased during the COVID-19 pandemic period, potentially reflecting delayed presentations and strained healthcare resources.

High-Yield Clinical Pearls

• AP is the most common GI cause of hospitalization in the US, with incidence rising ~3%–5% annually.
• Population-level case fatality is ~1%–2%, but this masks dramatic variation by severity (see Natural History microchapter for organ-failure and infected-necrosis rates).
• Gallstone AP predominates in women; alcohol-related AP predominates in men — but alcohol-related AP is now increasing in women.
• African Americans have 2× the AP risk, but American Indian/Alaska Native populations have the highest mortality.
• Pediatric AP is no longer rare — incidence of 3.6–13.2 per 100,000 overlaps with the lower adult range.
• Eastern Europe bears the highest global pancreatitis burden, driven largely by alcohol consumption.

Common Pitfalls

• Assuming AP is rare in children — it is now recognized as one of the more common pediatric GI diagnoses requiring hospitalization.
• Overlooking racial/ethnic disparities and social determinants of health in AP outcomes.
• Attributing the entire incidence increase to a true rise in disease without considering coding and diagnostic detection changes.
• Failing to recognize that overall population mortality has not declined despite lower case fatality, because incidence has increased.